Biofrontera Inc. (BFRI) director receives 20,000 stock options

Rhea-AI Filing Summary

Lanckriet Heikki reported acquisition or exercise transactions in this Form 4 filing.

Biofrontera Inc. director Heikki Lanckriet received a grant of employee stock options covering 20,000 shares on March 4, 2026. These options were awarded at a stated price of $0.0000 per share and represent a new direct derivative holding of 20,000 options.

The option grant vests in twelve equal monthly installments, beginning on April 4, 2026, spreading the benefit to the director over one year. The disclosure notes that options with different terms are not included in this reported amount.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lanckriet Heikki

(Last) (First) (Middle)

660 MAIN STREET

FIRST FLOOR

(Street)

WOBURN MA 01801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Biofrontera Inc. [ BFRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$0.9	03/04/2026		A		20,000		(1)	03/04/2036	Common Stock	20,000	$0	20,000(2)	D

Explanation of Responses:

1. The option vests in twelve equal monthly installments beginning on April 4, 2026.

2. Options with different terms are not included.

	/s/ Heikki Lanckriet	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Biofrontera Inc. (BFRI) report for Heikki Lanckriet?

Biofrontera Inc. reported that director Heikki Lanckriet received a grant of 20,000 employee stock options. The derivative award was made on March 4, 2026 and gives him rights to buy Biofrontera shares under the specified vesting schedule.

How many stock options did Biofrontera Inc. (BFRI) grant to director Heikki Lanckriet?

Heikki Lanckriet was granted 20,000 employee stock options. These options increase his direct derivative holdings to 20,000 options in total, according to the filing, and are structured to vest gradually over a one-year period.

What is the vesting schedule for Heikki Lanckriet’s Biofrontera (BFRI) stock options?

The 20,000 Biofrontera stock options vest in twelve equal monthly installments. Vesting begins on April 4, 2026, meaning a portion of the grant becomes exercisable each month over one year, aligning the award with ongoing service.

What exercise price is shown for Heikki Lanckriet’s Biofrontera (BFRI) option grant?

The filing lists a transaction price of $0.0000 per share for the 20,000 employee stock options. This reflects the terms recorded for the grant on March 4, 2026 in the Form 4 derivative transaction details.

How did the Biofrontera (BFRI) option grant affect Heikki Lanckriet’s holdings?

After the grant, Heikki Lanckriet directly holds 20,000 employee stock options. The Form 4 indicates this total derivative position following the transaction, with the options subject to the specified monthly vesting schedule starting April 4, 2026.